此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment

2026年11月11日 更新者:Reistone Biopharma Company Limited

A Pharmacokinetic Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment

This study is a single-center, single-dose, open-label study designed to evaluate the pharmacokinetic (PK) profile of RSS0343 tablets in healthy participants and in participants with mild or moderate renal impairment.

研究概览

研究类型

介入性

注册 (估计的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Henan
      • Zhengzhou、Henan、中国、450052
        • The First Affiliated Hospital of Zhengzhou University
        • 首席研究员:
          • Youhong Hu
        • 首席研究员:
          • Zhanzheng Zhao

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Participants voluntarily sign the informed consent form (ICF), have a full understanding of the purpose and significance of this study, and are willing to comply with the study protocol.
  2. Males or females aged 18 to 65 years (both boundaries inclusive).
  3. Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) = weight (kg) / height² (m²), with BMI within the range of 19 to 28 kg/m² (both boundaries inclusive).
  4. The absolute value of estimated glomerular filtration rate (eGFR) shall be calculated using the Modification of Diet in Renal Disease (MDRD) equation modified for the Chinese population (for the equation and calculation method). Participants with mild renal impairment: absolute eGFR of 60-89 mL/min; participants with moderate renal impairment: absolute eGFR of 30-59 mL/min (boundary values inclusive); healthy participants: absolute eGFR ≥ 90 mL/min and < 130 mL/min.
  5. Male and female participants of reproductive / childbearing potential and their partners must have no plan for pregnancy or for sperm / oocyte donation within 6 months (female participants) or 3 months (male participants) after the last dose, and must be willing to use highly effective contraceptive measures. Female participants of childbearing potential must have a negative serum pregnancy test prior to the first dose and must not be breastfeeding.
  6. (For participants with renal impairment, the following additional inclusion criteria must also be met) The participant has been diagnosed with chronic (> 3 months) and stable renal injury (no acute exacerbation due to deterioration of renal function within 1 month prior to screening), and medical records or laboratory reports confirming the diagnosis of renal impairment for more than 3 months must be provided.
  7. (Participants with normal renal function) Physical examination, 12-lead electrocardiogram (12-ECG), vital signs, chest imaging, abdominal ultrasonography (color Doppler ultrasound) and laboratory tests at screening and baseline are normal, or abnormal without clinical significance.

Exclusion Criteria:

  1. Those who smoked more than 5 cigarettes per day (or used an equivalent amount of other nicotine-containing products) within 3 months prior to screening, or who plan to use any tobacco products during the study.

  2. Regular alcohol drinkers within 6 months prior to screening (i.e., daily alcohol intake exceeding 15 g for females and 25 g for males [5 g of alcohol is equivalent to 150 mL of beer, 50 mL of wine, or approximately 17 mL of low-alcohol liquor], on more than 2 occasions per week) who are unable to abstain from any alcohol-containing products during the study; or those with a positive alcohol breath test at baseline.

  3. Those with a history of drug abuse, illicit drug use, or drug dependence (as determined by interview/medical history), or a positive urine drug screen at baseline.

  4. Blood donation or blood loss of ≥ 200 mL in total within 1 month prior to dosing, or ≥ 400 mL in total within 3 months prior to dosing; receipt of a blood transfusion within 8 weeks prior to dosing; difficult venipuncture, or a physical condition that cannot tolerate intensive blood collection.

  5. Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), syphilis antibody, or human immunodeficiency virus (HIV) antibody.

  6. Suspected allergy / hypersensitivity to the investigational product or any of its components, or a history of severe allergy to any drug, food, toxin, or other exposure.

  7. Any surgery within 3 months prior to screening, or incomplete recovery from surgery as judged by the investigator, or any surgery planned during the study period through 1 month after the end of the study.

  8. Participants who refuse to abstain from any methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, chocolate) from 48 hours prior to baseline until the end of the study; who refuse to abstain from any grapefruit-containing beverages or foods from 7 days prior to baseline until the end of the study; or who have special dietary requirements and are unable to comply with the standardized diet provided in the study.

  9. Receipt of any live vaccine or live-attenuated vaccine within 1 month prior to screening, or a requirement for vaccination with a live vaccine during study participation (including within 30 days after the last dose of the investigational product).

  10. Those who have participated in any clinical trials involving drugs or medical devices within three months prior to signing the informed consent form (or within five elimination half-lives of the studied drug, whichever is the longer period), excluding those who participated in other clinical trials but were not administered the drug due to screening failure.

    Exclusion criteria for participants with renal dysfunction:

  11. According to the judgment of the researchers, participants with renal dysfunction who are not suitable to participate in the study (such as those who have undergone kidney transplantation, those with urinary incontinence or anuria).

  12. Those who, in the investigator's judgment, have experienced marked fluctuation or rapid deterioration of renal function within 2 weeks prior to dosing.

  13. Those who have received renal replacement therapy (e.g., hemodialysis) within 3 months prior to screening, or who are expected to receive renal replacement therapy during the study.

  14. Those with underlying diseases contributing to chronic kidney disease (e.g., diabetes mellitus, hypertension) that have been poorly controlled within 3 months prior to screening, as judged by the investigator.

  15. Other than the primary renal disease itself, any history of serious disease, or any medical history and/or clinically significant abnormal clinical laboratory findings that, in the investigator's opinion, may affect the study results, including but not limited to a history of diseases of the circulatory, endocrine, nervous or digestive systems, or hematologic, immune, psychiatric or metabolic diseases.

  16. Use of any prescription drugs, over-the-counter (OTC) drugs, Chinese patent medicines or dietary supplements, other than those used for the treatment of renal impairment and other concomitant diseases, within 2 weeks prior to administration of the study drug; or use of strong inhibitors or inducers of CYP3A4 and/or P-glycoprotein (P-gp) within 2 weeks prior to administration of the study drug.

    Exclusion criteria for participants with normal renal function:

  17. Previous severe primary diseases of important organs, including but not limited to gastrointestinal, respiratory, renal, liver, nervous, hematological, endocrine, tumor, immune, mental or cardiovascular and cerebrovascular diseases.

  18. Use of any medication (including prescription drugs, over-the-counter drugs, herbal medicines, Chinese patent medicines, and dietary supplements) within 4 weeks prior to screening, or still within 5 half-lives of a drug at the time of screening (whichever is longer).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:RSS0343 Tablet Group

Administration of RSS0343 tablet.

RSS0343 tablet, oral.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The maximum plasma concentration (Cmax)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
The area under the blood drug concentration-time curve from Time 0 to the last quantifiable concentration time (AUC0-t)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
The area under the blood drug concentration-time curve from Time 0 to the extrapolated infinite time (AUC0-inf)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.

次要结果测量

结果测量
措施说明
大体时间
Time to maximum plasma concentration (Tmax)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Terminal half-life (t1/2)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Apparent clearance (CL/F)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Apparent volume of distribution (Vz/F)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Cumulative amount of drug excreted unchanged in urine (Ae)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Fraction of the administered dose excreted unchanged in urine (Fe)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Renal clearance (CLr)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Plasma protein binding (PPB)
大体时间:Day 1 - Day 12.

The PK Parameter.

Day 1 - Day 12.
Incidence and severity of adverse events (AEs)
大体时间:Day 1 - Day 12.

Safety Parameter.

Day 1 - Day 12.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年2月1日

研究完成 (估计的)

2027年4月1日

研究注册日期

首次提交

2026年11月11日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅